Stargardt disease is a genetic eye disorder that causes a progressive loss of central vision.
The vision loss is concentrated in the macula, the central area of the retina responsible for high-detail vision for tasks like face recognition or reading. The symptoms are similar to age related macular degeneration, but they are caused by inherited mutation and affect people much earlier in life.



Our Approach to Treatment
The PRIMA implant builds on decades of research to miniaturize solar technology. It is inserted into the subretinal space where the photoreceptors have degenerated, and electrical stimulation activates the remaining intact neurons to restore vision.
Learn more about PRIMACurrent Status
Science's PRIMAvera clinical study is focused on AMD and is ongoing in Europe. We are currently exploring the possibility of using the PRIMA implant with Stargardt patients.
Resources
More information about treatment options, disease details, and current research